Separately, the FDA on Friday informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, that is approved to treat a different type of muscular dystrophy and was ...

Sarepta stock (SRPT) declined 5% in premarket trade, after falling 36% on Friday, when it disclosed a patient death due to liver failure.

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an unrelated drug.

Sarepta Therapeutics faces challenges as the FDA halts gene therapy trials for LGMD and revokes AAVrh74 platform designation.

Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second ...

Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

The firm says that absent a bigger strategic shift, the company's sales will continue to underperform. Needham downgraded Sarepta (SRPT) to Underperform from Hold without a price target. The company ...

An unusual public feud between the Food and Drug Administration and a maker of gene therapies for rare diseases could test ...

While most investors chase yesterday's headlines, Tim Melvin spots tomorrow's winners. See the exact system that found NVIDIA ...